Pulmonary Embolism Risk Stratification and Management

Primary Risk Stratification Framework

The European Society of Cardiology recommends that risk stratification in pulmonary embolism is hierarchical and does not primarily depend on clot location 1, 2
High-risk pulmonary embolism is defined by hemodynamic instability, regardless of clot location, with a sustained hypotension of less than 90 mmHg, shock, or cardiac arrest 1, 4
Intermediate-risk pulmonary embolism requires both elevated PESI and evidence of right ventricular dysfunction on imaging or elevated cardiac biomarkers 3
Low-risk pulmonary embolism is identified by PESI Class I-II with no right ventricular dysfunction 3

The presence of right heart thrombi represents a critical exception where location significantly impacts prognosis, with a mortality rate of 21% versus 11% without right heart thrombi 6
Thrombolytic therapy is the only treatment independently associated with decreased mortality on multivariate analysis in patients with right heart thrombi 6
Right ventricular dysfunction on imaging, such as an RV/LV diameter ratio greater than 0.9 on computed tomography pulmonary angiography, is more prognostically relevant than anatomic location alone 1, 2, 3, 7

The European Society of Cardiology recommends assessing hemodynamic stability immediately in patients with elevated PESI, with systemic thrombolysis indicated for unstable patients 1, 2
Evaluating for right ventricular dysfunction via echocardiography or computed tomography pulmonary angiography is crucial, with specific attention to right heart thrombi 3, 6
Measuring cardiac biomarkers, such as troponin and NT-proBNP, helps classify patients into intermediate-high or intermediate-low risk, guiding management decisions 3, 7

The European Society of Cardiology establishes that hemodynamic status and right ventricular dysfunction drive management decisions in elevated PESI patients, not anatomic location 1, 2, 3
The specific finding of right heart thrombus represents an important exception where location does matter prognostically and may influence the decision for thrombolytic therapy 6